Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Novaccess Global Inc XSNX

NovAccess Global Inc. is a biopharmaceutical company, which develops immunotherapies to treat brain tumor patients in the United States. The Company specializes in research related to utilizing a patient’s own immune system to attack the cancer. Its dendritic cell-based immunotherapy utilizes a combination of Toll-like receptor adjuvants for an enhanced antitumor response. The therapy is designed to utilize the patient’s tumor antigens and immune cells, dendritic cells, in combination with TLR adjuvants to initiate an efficient antitumor immune response. This process includes obtaining the patients' tumor cells after surgery, and precursors cells that are matured into dendritic cells from peripheral blood. Its TLR-AD1 platform technology is a vaccine immunotherapy for the treatment of aggressive brain cancers, including glioblastoma and other high-grade gliomas. TLR-AD1 technology has a scope of use and is embodied in various different product lines for different clinical situations.


OTCPK:XSNX - Post by User

Bullboard Posts
Post by coloradonorthon Dec 02, 2009 7:17pm
372 Views
Post# 16547772

XsunX Reports on Executive Attendance at the Thin-

XsunX Reports on Executive Attendance at the Thin-

Letter to XsunX Shareholders:

XsunX Reports on Executive Attendance at the Thin-film Solar Summit U.S.

To Our Valued Shareholders,

We are excited to report that yesterday, XsunX's Chief Technology Officer, Robert Wendt, presented XsunX's novel manufacturing approach of Copper Indium Gallium diSelenide (CIGS) thin-film solar cells at the second annual Thin-film Solar Summit U.S. in San Francisco. Held at the Hotel Nikko San Francisco, the summit has become a prestigious event attracting a wide array of solar industry professionals from engineers and scientists to manufacturers and project developers.

Joined on stage by a panel of distinguished members of the thin-film solar community, Mr. Wendt explained to an audience of nearly 200 scientists and industry peers, aspects of the engineering, processing methods and science behind the rapid single cell manufacturing of thin-film CIGS cells using equipment adapted from the Hard Disk Drive industry.

During his presentation, Mr. Wendt delved into the benefits of XsunX's technology citing low risk, speed to market and economic viability as the main reasons why he believes XsunX will revolutionize the thin-film solar cell manufacturing industry.

Attendees and panelists alike showed tremendous interest with the content of his presentation, and the feedback we received via the numerous questions and comments was very positive. Mr. Wendt's presentation is available for viewing on the XsunX website at, https://www.xsunx.com/news-industry.htm
Through the balance of the commercialization process, we will continue to attend and present at conferences like this one as they provide excellent opportunities for relationship-building and allow us to keep our finger on the pulse of the solar industry. At the same time, we're cognizant of the attractiveness of our manufacturing approach and are being selective about which aspects we reveal and when, to ensure that we retain our competitive advantage."

These are exciting times at XsunX and we thank you for your continued support of XsunX. As new developments arise, we look forward to sharing them with you. In the meantime, if you have any questions, please contact our Investor Relations desk at investors@xsunx.com or (888) 797-4527.

Yours Truly,
Tom M. Djokovich, CEO
XsunX, Inc.

Safe Harbor Statement: Matters discussed in this shareholder news letter contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When used in this shareholder news letter, the words "anticipate," "believe," "estimate," "may," "intend," "expect" and similar expressions identify such forward-looking statements. Actual results, performance or achievements could differ materially from those contemplated, expressed or implied by the forward-looking statements contained herein. These forward-looking statements are based largely on the expectations of the Company and are subject to a number of risks and uncertainties. These include, but are not limited to, risks and uncertainties associated with: the impact of economic, competitive and other factors affecting the Company and its operations, markets, product, and distributor performance, the impact on the national and local economies resulting from terrorist actions, and U.S. actions subsequently; and other factors detailed in reports filed by the Company.

Bullboard Posts